Department for Parkinson's Disease, IRCSS San Camillo, Venice, Italy;
Neuropsychiatr Dis Treat. 2011;7:297-302. doi: 10.2147/NDT.S10097. Epub 2011 May 15.
Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson's disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course.
盐酸普拉克索普通片（IR）被批准用于特发性帕金森病（PD）的对症治疗，可单独使用（无左旋多巴）或与左旋多巴联合使用，即用于疾病的整个进展过程直至晚期。它目前也被批准用于治疗中重度原发性不安腿综合征（RLS）。为了实现每日一次的给药方案并提供更稳定的多巴胺能刺激，已开发出盐酸普拉克索的控释（ER）制剂。本文总结了 IR 和 ER 制剂的盐酸普拉克索的药代动力学特征，并讨论了普拉克索在早期和晚期 PD 管理中的作用。盐酸普拉克索每日一次的给药方案为患者带来了显著的潜在优势，这反映在相对稳定的血浆水平上。最明显的益处是使用方便和更好地遵循治疗计划。如果药物在疾病早期使用，还有可能提供持续的药物输送，从而潜在地有助于降低运动障碍风险，这可能是额外的优势。
